Brief: Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program In Multiple Sclerosis
03/02/2022 13:42
Feb 3 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS INITIATES NEW CHEMICAL ENTITY DRUG
DEVELOPMENT PROGRAM IN MULTIPLE SCLEROSIS
Source text for Eikon: ID:nGNX1FLVjz
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement